Axonics Inc Quick Ratio (AXNX) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Axonics Inc   (NASDAQ: AXNX)

Axonics Inc 's Quick Ratio

AXNX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 5.36 a new company low.

Within Medical Equipment & Supplies industry 29 other companies have achieved higher Quick Ratio than Axonics Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 292 to 643.

Explain Quick Ratio?
How much Cash & cash equivalents AXNX´s has?
What are AXNX´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AXNX/financial-strength
https://api.csimarket.com/api/v1/companies/AXNX/fundamentals
https://api.csimarket.com/api/v1/companies/AXNX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
AXNX Quick Ratio (Sep 30 2024)
Q3
(Jun 30 2024)
Q2
(Mar 31 2024)
Q1
(Dec 31 2023)
Q4
(Sep 30 2023)
Q3
Y / Y Current Liabilities Change 80.99 %
Y / Y Cash & cash equivalent Change 0.15 %
Quick Ratio MRQ 5.36
AXNX's Total Ranking # 643
Seq. Current Liabilities Change 12.67 %
Seq. Cash & cash equivalent Change 0.53 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 30
Healthcare Sector # 312
Overall Market # 643


Quick Ratio Statistics
High Average Low
38.42 9.55 5.36
(Dec 31 2018)   (Sep 30 2024)




Financial Statements
Axonics Inc 's Current Liabilities $ 64 Millions Visit AXNX's Balance sheet
Axonics Inc 's Cash & cash equivalent $ 345 Millions Visit AXNX's Balance sheet
Source of AXNX's Sales Visit AXNX's Sales by Geography


Cumulative Axonics Inc 's Quick Ratio

AXNX's Quick Ratio for the trailling 12 Months

AXNX Quick Ratio

(Sep 30 2024)
12 Months
(Jun 30 2024)
12 Months
(Mar 31 2024)
12 Months
(Dec 31 2023)
12 Months
(Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 8.39 %
Y / Y Cash & cash equivalent TTM Growth -1.73 %
Quick Ratio TTM 6.33
Total Ranking TTM # 3151
Seq. Current Liabilities TTM Growth 15.42 %
Seq. Cash & cash equivalent TTM Growth 0.04 %


On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2024 to $64.42 millions, cumulative Quick Ratio decreased to 6.33 below the Axonics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 192 other companies have achieved higher Quick Ratio than Axonics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 71 to 3151.

Explain Quick Ratio?
How much Cash & cash equivalents AXNX´s has?
What are AXNX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 193
Healthcare Sector # 899
Within the Market # 3151


trailing twelve months Quick Ratio Statistics
High Average Low
12.18 7.6 0.28
(Dec 31 2019)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Medical Equipment & Supplies Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Talkspace Inc   14.34 $ 118.994  Millions$ 8.299  Millions
Neurometrix Inc   13.90 $ 14.835  Millions$ 1.067  Millions
Bone Biologics Corporation  13.04 $ 3.566  Millions$ 0.273  Millions
Dror Ortho-Design, Inc.  12.75 $ 1.143  Millions$ 0.090  Millions
Pulse Biosciences Inc   11.72 $ 79.033  Millions$ 6.741  Millions
Inspire Medical Systems inc   11.50 $ 410.987  Millions$ 35.748  Millions
Inmode Ltd   11.23 $ 596.472  Millions$ 53.096  Millions
Rxsight Inc   10.47 $ 237.120  Millions$ 22.638  Millions
Orasure Technologies Inc  10.03 $ 278.571  Millions$ 27.784  Millions
Perspective Therapeutics Inc   9.52 $ 267.847  Millions$ 28.143  Millions
Cvrx inc   9.15 $ 100.161  Millions$ 10.947  Millions
Sight Sciences Inc   8.59 $ 118.564  Millions$ 13.799  Millions
Vicarious Surgical Inc  8.19 $ 60.864  Millions$ 7.429  Millions
Retractable Technologies Inc  7.50 $ 36.700  Millions$ 4.891  Millions
Modular Medical Inc  7.18 $ 6.986  Millions$ 0.973  Millions
Innovative Eyewear Inc   6.96 $ 4.544  Millions$ 0.653  Millions
Alpha Pro Tech Ltd   6.80 $ 18.394  Millions$ 2.706  Millions
Monogram technologies inc   6.50 $ 16.565  Millions$ 2.547  Millions
Co diagnostics Inc   6.50 $ 37.662  Millions$ 5.798  Millions
Iradimed Corporation  6.41 $ 51.721  Millions$ 8.063  Millions
Irhythm Holdings Inc   6.40 $ 522.031  Millions$ 81.551  Millions
Inspiremd Inc   5.56 $ 40.402  Millions$ 7.265  Millions
Transmedics Group Inc   5.50 $ 330.094  Millions$ 60.048  Millions
Bluejay Diagnostics Inc  5.49 $ 5.756  Millions$ 1.049  Millions
Fractyl Health Inc   5.39 $ 84.664  Millions$ 15.717  Millions
Axonics Inc   5.36 $ 345.225  Millions$ 64.419  Millions
Tactile Systems Technology Inc   5.11 $ 82.146  Millions$ 16.088  Millions
Nakamoto Inc   5.03 $ 3.654  Millions$ 0.726  Millions
Hyperfine Inc   4.60 $ 45.765  Millions$ 9.959  Millions
Nutriband Inc   4.57 $ 5.698  Millions$ 1.248  Millions

Date modified: 2026-10-22T14:09:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.